These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 9491832

  • 1. Antioxidant power of angiotensin-converting enzyme inhibitors in vitro.
    Benzie IF, Tomlinson B.
    Br J Clin Pharmacol; 1998 Feb; 45(2):168-9. PubMed ID: 9491832
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Effects of in vitro addition of captopril on copper-induced low density lipoprotein oxidation.
    Ziedén B, Wuttge DM, Karlberg BE, Olsson AG.
    Br J Clin Pharmacol; 1995 Feb; 39(2):201-3. PubMed ID: 7742164
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The influence of angiotensin-converting enzyme inhibitors on the aorta elastin metabolism in diet-induced hypercholesterolaemia in rabbits.
    Wojakowski W, Gminski J, Siemianowicz K, Goss M, Machalski M.
    J Renin Angiotensin Aldosterone Syst; 2001 Mar; 2(1):37-42. PubMed ID: 11881065
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Inhibitory effects of angiotensin-converting enzyme inhibitor on cefroxadine uptake by rabbit small intestinal brush border membrane vesicles.
    Kitagawa S, Takeda J, Kaseda Y, Sato S.
    Biol Pharm Bull; 1997 Apr; 20(4):449-51. PubMed ID: 9145229
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Captopril inhibits the oxidative modification of apolipoprotein B-100 caused by myeloperoxydase in a comparative in vitro assay of angiotensin converting enzyme inhibitors.
    Van Antwerpen P, Legssyer I, Zouaoui Boudjeltia K, Babar S, Moreau P, Moguilevsky N, Vanhaeverbeek M, Ducobu J, Nève J.
    Eur J Pharmacol; 2006 May 10; 537(1-3):31-6. PubMed ID: 16631159
    [Abstract] [Full Text] [Related]

  • 15. Effect of enalapril and quinapril on forearm vascular ACE in man.
    Lyons D, Webster J, Benjamin N.
    Eur J Clin Pharmacol; 1997 May 10; 51(5):373-8. PubMed ID: 9049577
    [Abstract] [Full Text] [Related]

  • 16. Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update.
    Song JC, White CM.
    Clin Pharmacokinet; 2002 May 10; 41(3):207-24. PubMed ID: 11929321
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetic interaction between cefdinir and two angiotensin-converting enzyme inhibitors in rats.
    Jacolot A, Tod M, Petitjean O.
    Antimicrob Agents Chemother; 1996 Apr 10; 40(4):979-82. PubMed ID: 8849263
    [Abstract] [Full Text] [Related]

  • 18. Differences in first dose response to angiotensin converting enzyme inhibition in congestive heart failure: a placebo controlled study.
    MacFadyen RJ, Lees KR, Reid JL.
    Br Heart J; 1991 Sep 10; 66(3):206-11. PubMed ID: 1657084
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.